Progyny (PGNY) Stock Forecast & Price Target

Progyny is supported by a differentiated fertility benefits platform that combines Smart Cycles, a curated clinician network, active provider management, and high-touch care advocates, all of which help deliver superior outcomes and stronger member satisfaction. Its competitive position appears durable, with retention above 99%, more than 50% win rates in evaluated deals, and roughly 7 million covered lives served out of a roughly 105 million self-insured market, leaving substantial room for share gains and broader penetration. Recent momentum is reinforced by CalPERS’ selection, 1Q26 revenue and EBITDA beating consensus by 1% and 6%, and raised 2026 revenue and EBITDA guidance, while investments in AI, platform modernization, and Progyny Select should support long-term efficiency and expansion.

Progyny is facing a negative outlook because its growth depends heavily on covered lives, yet elevated attrition, utilization pressure, and an economic downturn could slow membership gains and employer adoption of fertility benefits. Its revenue is also exposed to competitive threats, slower-than-expected new solution sales, and political uncertainty around reproductive rights, while the loss of Amazon and a broadened stock-based compensation burden highlight customer and margin fragility. Although management cites roughly 6.9 million eligible members, a target of about 1 million new covered lives annually, and recent renewal strength, those supports may not offset volatility in demand or protect against further customer concentration and revenue execution risk.